Literature DB >> 32008226

Prognostic value of non-alcoholic fatty liver disease in the elderly patients.

Viola Tallarico1, Guerino Recinella2, Donatella Magalotti1, Antonio Muscari1, Marco Zoli1, Giampaolo Bianchi1.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of metabolic syndrome, a risk factor for mortality and cardiovascular morbidity, but we ignore the role of steatosis per se in survival, and there is very little information about this condition in the geriatric patient. AIMS: With the present study, we investigated the independent prognostic value of NAFLD on overall mortality in the elderly.
METHODS: Within the Pianoro Project, involving people ≥ 65 years, anamnestic, clinical and laboratoristic data related to NAFLD, insulin resistance, diabetes/hyperglycemia, hypertension, obesity and dyslipidemia were collected in 804 subjects (403 male, 401 female). These subjects were followed up for mortality for a median time of 12.6 years. A multivariate analysis was performed to evaluate the prognostic value of the covariates.
RESULTS: At Kaplan-Meier estimator the presence of NAFLD seems to be associated to a lower mortality, and survival tends to increase with the increasing of steatosis grade. Cox's analysis found that survival is increased for subjects having hypercholesterolemia (RR = 0.565), NAFLD (RR = 0.777), hypertension (RR = 0.711) and in female (RR = 0.741), while it is decreased for the older subjects (RR = 3.046), in patients with hypertriglyceridemia (RR = 1.699) and for diabetics (RR = 1.797). The variables BMI and HDL-cholesterol have no role.
CONCLUSION: The data obtained in our study show that NAFLD is not associated to overall mortality in the elderly population.

Entities:  

Keywords:  Diabetes; Elderly; Metabolic syndrome; Non-alcoholic fatty liver disease

Mesh:

Year:  2020        PMID: 32008226     DOI: 10.1007/s40520-020-01487-2

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  21 in total

Review 1.  Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.

Authors:  Amedeo Lonardo; Stefano Bellentani; Curtis K Argo; Stefano Ballestri; Christopher D Byrne; Stephen H Caldwell; Helena Cortez-Pinto; Antonio Grieco; Mariana V Machado; Luca Miele; Giovanni Targher
Journal:  Dig Liver Dis       Date:  2015-08-14       Impact factor: 4.088

2.  The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease.

Authors:  Yuichiro Eguchi; Toshihiko Mizuta; Yoshio Sumida; Eriko Ishibashi; Yoichiro Kitajima; Hiroshi Isoda; Hiroko Horie; Takaya Tashiro; Eri Iwamoto; Hirokazu Takahashi; Takuya Kuwashiro; Shu Soejima; Yasunori Kawaguchi; Yasutomo Oda; Sei Emura; Ryuichi Iwakiri; Iwata Ozaki; Takahisa Eguchi; Naofumi Ono; Keizo Anzai; Kazuma Fujimoto; Shunzo Koizumi
Journal:  J Gastroenterol       Date:  2010-11-02       Impact factor: 7.527

3.  Response to: Comment to "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease".

Authors:  Giulio Marchesini; Michael Roden; Roberto Vettor
Journal:  J Hepatol       Date:  2016-11-14       Impact factor: 25.083

4.  Cooperation of C/EBP family proteins and chromatin remodeling proteins is essential for termination of liver regeneration.

Authors:  Jingling Jin; Il-Hwa Hong; Kyle Lewis; Polina Iakova; Meghan Breaux; Yanjun Jiang; Emily Sullivan; Nicole Jawanmardi; Lubov Timchenko; Nikolai A Timchenko
Journal:  Hepatology       Date:  2014-11-20       Impact factor: 17.425

5.  Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study.

Authors:  Angel Brea; Daniel Mosquera; Eva Martín; Ana Arizti; José L Cordero; Emilio Ros
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM.

Authors:  S M Haffner; M Hanefeld; S Fischer; K Fuçker; W Leonhardt
Journal:  Diabetes Care       Date:  1997-09       Impact factor: 19.112

8.  The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up.

Authors:  David E Jones; Ahmad Al-Rifai; James Frith; Imran Patanwala; Julia L Newton
Journal:  J Hepatol       Date:  2010-08-01       Impact factor: 25.083

9.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Authors:  E Bugianesi; A Gastaldelli; E Vanni; R Gambino; M Cassader; S Baldi; V Ponti; G Pagano; E Ferrannini; M Rizzetto
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

Review 10.  Pathophysiology of nonalcoholic steatohepatitis.

Authors:  Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2006-03       Impact factor: 3.062

View more
  2 in total

1.  Prognostic role of nutritional status in elderly patients hospitalized for COVID-19: a monocentric study.

Authors:  Guerino Recinella; Giovanni Marasco; Giovanni Serafini; Lorenzo Maestri; Giampaolo Bianchi; Paola Forti; Marco Zoli
Journal:  Aging Clin Exp Res       Date:  2020-10-08       Impact factor: 3.636

2.  Sarcopenia modifies the associations of nonalcoholic fatty liver disease with all-cause and cardiovascular mortality among older adults.

Authors:  Xingxing Sun; Zhelong Liu; Fuqiong Chen; Tingting Du
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.